Heat-shock proteins in clinical neurology

European Neurology

Volumn 66, Issue 2, 2011, Pages 65-69

  Romi, Fredrik ^a   Helgeland, Geir ^b   Gilhus, Nils Erik ^a,b  

^a HAUKELAND UNIVERSITY HOSPITAL   (Norway)

^b UNIVERSITY OF BERGEN   (Norway)

Author keywords

Epilepsy; Guillain Barr syndrome; Heat shock proteins; Multiple sclerosis; Myasthenia gravis; Stroke

Indexed keywords

ALPHA CRYSTALLIN; BETA CRYSTALLIN; COPPER ZINC SUPEROXIDE DISMUTASE; HEAT SHOCK PROTEIN; HEAT SHOCK PROTEIN 27; HEAT SHOCK PROTEIN 27 ANTIBODY; HEAT SHOCK PROTEIN 70; HEAT SHOCK PROTEIN 70 ANTIBODY; HEAT SHOCK PROTEIN 71; HEAT SHOCK PROTEIN 71 ANTIBODY; IMMUNOSUPPRESSIVE AGENT; MUSCLE SPECIFIC KINASE; PROTEIN ANTIBODY; PROTEIN KINASE; UNCLASSIFIED DRUG;

ANTIBODY BLOOD LEVEL; ANTIGEN PRESENTATION; DEGENERATIVE DISEASE; DRUG RESPONSE; EPILEPSY; GUILLAIN BARRE SYNDROME; HUMAN; IMMUNOLOGICAL TOLERANCE; IMMUNOSUPPRESSIVE TREATMENT; MOLECULAR PATHOLOGY; MULTIPLE SCLEROSIS; MYASTHENIA GRAVIS; NEUROLOGIC DISEASE; NONHUMAN; PRIORITY JOURNAL; PROTEIN AGGREGATION; PROTEIN CEREBROSPINAL FLUID LEVEL; REVIEW; STROKE;

HEAT-SHOCK PROTEINS; HUMANS; NERVOUS SYSTEM DISEASES; NEUROLOGY;

EID: 79960236315     PISSN: 00143022     EISSN: 14219913     Source Type: Journal    
DOI: 10.1159/000329373     Document Type: Review

References (49)

1. Multhoff G: Heat-shock protein 70 (Hsp70): Membrane location, export and immunological relevance. Methods 2007; 43: 229-237. (Pubitemid 47499077)
2. Bukau B, Horwich AL: The Hsp70 and Hsp60 chaperone machines. Cell 1998; 92: 351-366. (Pubitemid 28093013)
3. Tsan MF, Gao B: Heat-shock protein and innate immunity. Cell Mol Immunol 2004; 1: 274-279.
4. Li Z, Menoret A, Srivastava P: Roles of heatshock proteins in antigen presentation and cross-presentation. Curr Opin Immunol 2002; 14: 45-51. (Pubitemid 34085106)
5. Wang Y, Kelly CG, Singh M, McGowan EG, Carrara AS, Bergmeier LA, Lehner T: Stimulation of Th1-polarizing cytokines, C-C chemokines, maturation of dendritic cells, and adjuvant function by the peptide binding fragment of heat-shock protein 70. J Immunol 2002; 169: 2422-2429. (Pubitemid 34920985)
6. Asea A, Kraeft SK, Kurt-Jones EA, Stevenson MA, Chen LB, Finberg RW, Koo GC, Calderwood SK: HSP70 stimulates cytokine production through a CD14-dependent pathway, demonstrating its dual role as a chaperone and cytokine. Nat Med 2000; 6: 435-442. (Pubitemid 30208161)
7. Tebo AE, Szankasi P, Hillman TA, Litwin CM, Hill HR: Antibody reactivity to heatshock protein 70 and inner ear-specific proteins in patients with idiopathic sensorineural hearing loss. Clin Exp Immunol 2006; 146: 427-432. (Pubitemid 44722160)
8. Tasneem S, Islam N, Ali R: Cross-reactivity of SLE autoantibodies with 70 kDa heatshock proteins of Mycobacterium tuberculosis Microbiol Immunol 2001; 45: 841-846. (Pubitemid 34019549)
9. Zlacka D, Vavrincova P, Hien Nguyen TT, Hromadnikova I: Frequency of anti-Hsp-60, -65 and -70 antibodies in sera of patients with juvenile idiopathic arthritis. J Autoimmun 2006; 27: 81-88. (Pubitemid 44550085)
10. Yusuf N, Nasti TH, Huang CM, Huber BS, Jaleel T, Lin HY, Xu H, Elmets CA: Heatshock proteins HSP27 and HSP70 are present in the skin and are important mediators of allergic contact hypersensitivity. J Immunol 2009; 182: 675-683.
11. Birtas-Atesoglu E, Inanc N, Yavuz S, Ergun T, Direskeneli H: Serum levels of free heatshock protein 70 and anti-HSP70 are elevated in Behçet's disease. Clin Exp Rheumatol 2008; 26:S96-S98.
12. Ratanachaiyavong S, Demaine AG, Campbell RD, McGregor AM: Heat-shock protein 70 (HSP70) and complement C4 genotypes in patients with hyperthyroid Graves' disease. Clin Exp Immunol 1991; 84: 48-52.
13. Hunt PJ, Marshall SE, Weetman AP, Bunce M, Bell JI, Wass JA, Welsh KI: Histocompatibility leucocyte antigens and closely linked immunomodulatory genes in autoimmune thyroid disease. Clin Endocrinol (Oxf) 2001; 55: 491-499. (Pubitemid 32955487)
14. Zhang ZY, Zhang Z, Schluesener HJ: Tolllike receptor-2, CD14 and heat-shock protein 70 in inflammatory lesions of rat experimental autoimmune neuritis. Neuroscience 2009; 159: 136-142.
15. Millar DG, Garza KM, Odermatt B, Elford AR, Ono N, Li Z, Ohashi PS: Hsp70 promotes antigen-presenting cell function and converts T-cell tolerance to autoimmunity in vivo. Nat Med 2003; 9: 1469-1476. (Pubitemid 38004773)
16. Stetler RA, Gao Y, Signore AP, Cao G, Chen J: HSP27: Mechanisms of cellular protection against neuronal injury. Curr Mol Med 2009; 9: 863-872.
17. Lindstrøm JM, Seybold ME, Lennon VA, Whittingham S, Duane DD: Antibody to acetylcholine receptor in myasthenia gravis: Prevalence, clinical correlates, and diagnostic value. 1975 classical article. Neurology 1998; 51: 933-939.
18. Luchanok U, Kaminski HJ: Ocular myasthenia: Diagnostic and treatment recommendations and the evidence base. Curr Opin Neurol 2008; 21: 8-15.
19. Evoli A, Batocchi AP, Minisci C, Di Schino C, Tonali P: Therapeutic options in ocular myasthenia gravis. Neuromuscul Disord 2001; 11: 208-216. (Pubitemid 32201147)
20. Wilcox N: Myasthenia gravis. Curr Opin Immunol 1993; 5: 910-917.
21. Li Z, Forester N, Vincent A: Modulation of acetylcholine receptor function in TE671 (rhabdomyosarcoma) cells by non-AchR ligands: Possible relevance to seronegative myasthenia gravis. J Neuroimmunol 1996; 64: 179-183. (Pubitemid 26094634)
22. Hoch W, McConville J, Helms S, Newsom-Davis J, Melms A, Vincent A: Auto-antibodies to the receptor tyrosine kinase MuSK in patients with myasthenia gravis without acetylcholine receptor antibodies. Nat Med 2001; 7: 365-368. (Pubitemid 32224355)
23. McConville J, Farrugia ME, Beeson D, Kishore U, Metcalfe R, Newsom-Davis J, Vincent A: Detection and characterization of MuSK antibodies in seronegative myasthenia gravis. Ann Neurol 2004; 55: 580-584. (Pubitemid 38391977)
24. Fuhrer C, Sugiyama JE, Taylor RG, Hall ZW: Association of muscle-specific kinase MuSK with the acetylcholine receptor in mammalian muscle. EMBO J 1997; 16: 4951-4960. (Pubitemid 27348404)
25. Borges LS, Ferns M: Agrin-induced phosphorylation of the acetylcholine receptor regulates cytoskeletal anchoring and clustering. J Cell Biol 2001; 153: 1-11. (Pubitemid 34280189)
26. Romi F, Skeie GO, Gilhus NE, Aarli JA: Striational antibodies in myasthenia gravis: Reactivity and possible clinical significance. Arch Neurol 2005; 62: 442-446. (Pubitemid 40349480)
27. Munakata S, Chen M, Aosai F, Kawaguchi N, Nemoto Y, Norose K, Hattori T, Yano A: The clinical significance of anti-heat-shock cognate protein 71 antibody in myasthenia gravis. J Clin Neurosci 2008; 15: 158-165. (Pubitemid 350298901)
28. Helgeland G, Petzold A, Hoff JM, Gilhus NE, Plant GT, Romi FR: Anti-heat-shock protein 70 antibody levels are increased in myasthenia gravis and Guillain-Barré syndrome. J Neuroimmunol 2010; 225: 180-183.
29. Yonekura K, Yokota S, Tanaka S, Kubota H, Fujii N, Matsumoto H, Chiba S: Prevalence of anti-heat-shock protein antibodies in cerebrospinal fluids of patients with Guillain-Barré syndrome. J Neuroimmunol 2004; 156: 204-209. (Pubitemid 39304201)
30. Salvetti M, Ristori G, Buttinelli C, Fiori P, Falcone M, Britton W, Adams E, Paone G, Grasso MG, Pozzilli C: The immune response to mycobacterial 70-kDa heat-shock proteins frequently involves autoreactive T cells and is quantitatively dysregulated in multiple sclerosis. J Neuroimmunol 1996; 65: 143-153. (Pubitemid 26198096)
31. Ce P, Erkizan O, Gedizlioglu M: Elevated HSP27 levels during attacks in patients with multiple sclerosis. Acta Neurol Scand 2011 (Epub ahead of print).
32. Stoevring B, Vang O, Christiansen M: α,β-crystallin in cerebrospinal fluid of patients with multiple sclerosis. Clin Chim Acta 2005; 356: 95-101. (Pubitemid 40779889)
33. Van Noort JM, Verbeek R, Meilof JF, Polman CH, Amor S: Autoantibodies against α,β-crystallin, a candidate autoantigen in multiple sclerosis, are part of a normal human immune repertoire. Mult Scler 2006; 12: 287-293. (Pubitemid 43827183)
34. Sinclair C, Mirakhur M, Kirk J, Farrell M, McQuaid S: Up-regulation of osteopontin and α,β-crystallin in the normal-appearing white matter of multiple sclerosis: An immunohistochemical study utilizing tissue microarrays. Neuropathol Appl Neurobiol 2005; 31: 292-303. (Pubitemid 40769528)
35. Steinman L: A molecular trio in relapse and remission in multiple sclerosis. Nat Rev Immunol 2009; 9: 440-447.
36. Azarpazhooh MR, Mobarra N, Parizadeh SM, Tavallaie S, Bagheri M, Rahsepar AA, Ghayour-Mobarhan M, Sahebkar A, Ferns GA: Serum high-sensitivity C-reactive protein and heat-shock protein 27 antibody titers in patients with stroke and 6-month prognosis. Angiology 2010; 61: 607-612.
37. Liebelt B, Papapetrou P, Ali A, Guo M, Ji X, Peng C, Rogers R, Curry A, Jimenez D, Ding Y: Exercise preconditioning reduces neuronal apoptosis in stroke by up-regulat -ing heat-shock protein-70 (heat-shock protein-72) and extracellular-signal-regulatedkinase 1/2. Neuroscience 2010; 166: 1091-1100.
38. Van der Weerd L, Tariq Akbar M, Aron Badin R, Valentim LM, Thomas DL, Wells DJ, Latchman DS, Gadian DG, Lythgoe MF, de Belleroche JS: Overexpression of heat-shock protein 27 reduces cortical damage after cerebral ischemia. J Cereb Blood Flow Metab 2010; 30: 849-856.
39. Goldstein LB: Physical activity and the risk of stroke. Expert Rev Neurother 2010; 10: 1263-1265.
40. Zhang F, Wu Y, Jia J: Exercise preconditioning and brain ischemic tolerance. Neuroscience 2011; 177: 170-176.
41. Bidmon HJ, Görg B, Palomero-Gallagher N, Behne F, Lahl R, Pannek HW, Speckmann EJ, Zilles K: Heat-shock protein-27 is upregulated in the temporal cortex of patients with epilepsy. Epilepsia 2004; 45: 1549-1559. (Pubitemid 39648280)
42. Xi ZQ, Sun JJ, Wang XF, Li MW, Liu XZ, Wang LY, Zhu X, Xiao F, Li JM, Gong Y, Guan LF: HSPBAP1 is found extensively in the anterior temporal neocortex of patients with intractable epilepsy. Synapse 2007; 61: 741-747. (Pubitemid 47122746)
43. Sarnat HB, Flores-Sarnat L: α,β-crystallin as a tissue marker of epileptic foci in paediatric resections. Can J Neurol Sci 2009; 36: 566-574.
44. Di Domenico F, Sultana R, Tiu GF, Scheff NN, Perluigi M, Cini C, Butterfield DA: Protein levels of heat-shock proteins 27, 32, 60, 70, 90 and thioredoxin-1 in amnestic mild cognitive impairment: An investigation on the role of cellular stress response in the progression of Alzheimer disease. Brain Res 2010; 1333: 72-81.
45. Ecroyd H, Carver JA: The effect of small molecules in modulating the chaperone activity of α,β-crystallin against ordered and disordered protein aggregation. FEBS J 2008; 275: 935-947. (Pubitemid 351230209)
46. Khandelwal PJ, Dumanis SB, Feng LR, Maguire-Zeiss K, Rebeck G, Lashuel HA, Moussa CE: Parkinson-related parkin reduces α -synuclein phosphorylation in a gene transfer model. Mol Neurodegener 2010; 5: 47.
47. Grünewald A, Voges L, Rakovic A, Kasten M, Vandebona H, Hemmelmann C, Lohmann K, Orolicki S, Ramirez A, Schapira AH, Pramstaller PP, Sue CM, Klein C: Mutant parkin impairs mitochondrial function and morphology in human fibroblasts. PLoS One 2010; 5:e12962.
48. Braak H, Del Tredici K, Sandmann-Kiel D, Rüb U, Schultz C: Nerve cells expressing heat-shock proteins in Parkinson's disease. Acta Neuropathol 2001; 102: 449-454. (Pubitemid 32976077)
49. Karch CM, Borchelt DR: An examination of α,β-crystallin as a modifier of SOD-1 aggregate pathology and toxicity in models of familial amyotrophic lateral sclerosis. J Neurochem 2010; 113: 1092-1100.